Tech

Eric Leire: How Biotechnology Can Contribute To Longevity Research

Published

5 years ago

August 6, 2021

Dr. Eric Leire, MD, MBA, is the CEO and Founder of GenFlow Biosciences. He has an impressive background in the biotechnology and gene therapy sector. Furthermore, Eric has a plethora of remarkable experience in the pharmaceutical industry, having held Pfizer, Schering Plough, and Pharmacia posts. His success has also translated into academic research, where he has held a research position at Harvard University.

In addition, his career has soared throughout the biotechnology industry, being the CEO of several private and public biotech companies. He is also the inventor of several patents and serves on the board of several biotechnology companies, such as Pherecydes (ALPHE.PA), Immunethep (developing a Covid vaccine), Inhatarget, and BSIM.

With the Biotech sector forecast to grow close to $2.5 trillion by 2028 – the financial benefits are straightforward and the moral importance to serve societal needs. In addition, research into longevity and healthy aging have progressed rapidly in recent years. We chatted with Eric, who explains how developments in the biotechnology sector can aid the longevity research process.

“Many US biotech companies shifted their research focus to improving longevity. However, only a few European biotech companies are working on a science-based development of therapeutic interventions that could delay the aging process.”

He continues, “Our company is interested in identifying the genetic and molecular pathways underpinning the aging process.” Specifically, Genflow Biosciences’ work is based on the fact that DNA repair plays a crucial role in determining an organism’s lifespan. As humans and other mammals grow older, our DNA is more and more prone to breaks. GenFlow intends to provide extra copies of a gene involved in DNA repair called SIRT6 and, more specifically, a variant of the SIRT6 found in centenarians. The additional copies of centenarian SIRT6 will improve the ability to repair DNA damage.

The feasibility of gene transfer to patients was demonstrated around 30 years ago and these methods have improved substantially. As a result, many commercial gene therapy candidates are now focussing on gene therapy for multiple diseases.

Scientists now can inject more efficient AAVs that can express a transgene such as SIRT6 into specific cells. Like other viruses, the tropism of an AAV for particular cells is controlled by the particular interaction between the proteins of its capsid (the protein shell enclosing the AAV genetic material) and the receptors of the targeted cells. In the last decade, there has been a tremendous advance in the ability to design novel, highly efficient AAVs that can target specific cells or organs.

Having a toolbox of enhanced AAVs is an important step; however, to develop an effective SIRT6 gene delivery, we also needed an understanding of the potential immunity to AAVs. A pre-existing barrier to AAV gene delivery stems from our natural exposure to AAV, resulting in a possible pre-existing humoral and cellular immunity to AAVs. Even a highly efficient and specific AAV delivering an ideal transgene (such as SIRT6) means nothing if an immune response prevents the AAV from reaching the appropriate cells. Therefore, it is critical when translating AAV gene delivery for clinical applications first to determine whether the patient has pre-existing immunity to AAV and then mitigate the development of potentially damaging immune responses when the gene is delivered intravenously. Fortunately, several studies have assessed the immune response to AAV-mediated gene therapy in both pre-clinical models and human patients. Overcoming pre-existing immunity is not trivial, but we now have strategies to enable AAV treatment without triggering immunity.

Eric believes that GenFlow’s contribution to advancing the understanding of anti-AAV immunity in our pre-clinical program. During clinical trials will help not only the development of our product but will also participate in the development of other safe and highly efficacious AAV therapies for other diseases such as neurodegenerative diseases, cardiovascular diseases, and cancer.

Tech

My Main AI Turns Complex Workflows into Simple, Voice-Driven Conversations

Published

2 days ago

February 9, 2026

Jonathan Grilli

Photo Courtesy of My Main AI Inc.

By: Chelsie Carvajal

Managing modern workflows often means juggling dashboards, documents, and long email threads before a single task is complete. My Main AI Inc, an AI technology platform that spans text, image, voice, and video, has built a system where many of those steps can be handled through spoken or written prompts instead of manual clicks.

Turning Tasks Into Conversations

My Main AI groups several automation tools around a voice and chat layer so users can move through work by giving instructions rather than configuring each step. The platform lists AI Web Chat, AI Realtime Voice Chat, AI Speech‑to‑Text Pro, and AI Text‑to‑Speech engines from providers such as Lemonfox, Speechify, and IBM Watson, creating a loop between spoken input and generated output.

Speech‑to‑text tools support accurate transcription of audio content in multiple languages, with options to translate those recordings into English. That capability gives businesses a way to record meetings, calls, or field conversations, then convert the results into text that can be summarized, edited, and turned into documents or scripts. Text‑to‑speech tools, including multi‑voice synthesis with up to 20 voices and SSML controls, take written content in the other direction, producing voiceovers for training, marketing, and support material.

Chat assistants extend the same pattern to files and websites. My Main AI lists AI Chat PDF, AI Chat CSV, and AI Web Chat, which allow users to ask questions of documents or site content through natural language prompts. Instead of sorting through long reports, a user can query a file, receive concise answers, and then send follow‑up requests to generate emails, briefs, or summaries in the same environment.

From Content Pipelines to Voice‑Led Workflows

The company reports that its platform connects to more than 100 models from OpenAI, Anthropic, Google Gemini, xAI, Amazon Bedrock and Nova, Perplexity, DeepSeek, Flux, Nano Banana, Google Veo, and Stable Diffusion 3.5 Flash. Public materials state that these models support text, image, voice, and video generation in more than 53 languages, giving the voice‑driven tools reach across several regions and markets.

Content creation sits at the center of many of these workflows. My Main AI offers modules for blog posts, email campaigns, ad copy, social captions, video scripts, and structured frameworks such as AIDA, PAS, BAB, and PPPP. A user can dictate key points or paste a brief into the chat, receive draft text, ask the assistant to adjust tone or length, and then pass the result into voice synthesis to create a narrated version.

Visual tools fit into the same flow. DALL·E 3 HD, Stable Image Ultra, and an AI Photo Studio support image creation, product mock‑ups, background changes, and multiple variations from a single upload. AI Image to Video and text‑to‑video connections with engines such as Sora and Google Veo, alongside an AI Avatar feature labeled “coming soon,” make it possible to turn a spoken or typed brief into images, then into short clips that accompany the newly generated audio.

Why Businesses See Conversation as Infrastructure

Company data shared with partners cites more than 77,000 customers worldwide, annual revenue near 3 million dollars, and monthly revenue growth around 250,000 dollars, driven largely by subscription sales. The 49‑dollar plan is described as the best‑selling tier, with My Main AI presenting it as the entry point to the broader suite of conversational and automation tools.

Business‑oriented features show how these voice‑driven workflows connect to operations. The platform lists payment gateways such as AWDpay and Coinremitter, integrations with Stripe, Xero, HubSpot, and Mailchimp, and tools for SEO, finance analytics, dynamic pricing, wallet systems, and referrals. A manager can ask a chat assistant to pull figures, draft a report, and prepare customer messages, then move directly into sending campaigns or reviewing payments through linked services.

Company communications describe ongoing work on proprietary models, expanded training flows from text, PDFs, and URLs, and deeper tools for chat, analytics, and video. That roadmap suggests that My Main AI views conversation—spoken or typed—as a central control surface for complex workflows, with automation stepping in behind the scenes so users can focus on clear instructions rather than manual configuration.